Stem Cell Sector Gets a Healthy Shot in the Arm
After a relatively tough year for stem cell companies on the public markets, they finally had something to cheer about – a regulatory milestone that could pave the way for a number of future approvals of stem cell therapies currently in late-stage clinical trials. The breakthrough event was Health Canada's approval of Prochymal (remestemcel-L), Osiris Therapeutics Inc.'s allogeneic stem cell treatment for graft-vs.-host disease (GvHD) in children.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST